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Teaching Case
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Introduction
The novel coronavirus disease 2019 (COVID-19),
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a pandemic affecting
health care centers across the globe. With an estimated
case fatality rate of 3.5%1,2 and a wide range of age
groups affected, providers are rapidly adjusting their
patterns of care to mitigate the negative impact of infection to cancer patients. In particular, oncologic patients
have been reported to be at increased risk of infection and
at a greater risk of severe events.1 As such, patients

Sources of support: Supported in part by Cancer Center Support
(Core) Grant CA016672 from the National Cancer Institute, National
Institutes of Health, USA, to The University of Texas MD Anderson
Cancer Center.
Disclosures: The authors report no conﬂicts of interest, ﬁnancial or
otherwise, to disclose with respect to this work.
Research data are not available at this time.
* Corresponding author: Steven H. Lin, MD, PhD; E-mail: shlin@
mdanderson.org.
1
Co-ﬁrst authors.

undergoing active cancer therapy are considered more
vulnerable to signiﬁcant morbidity from COVID-19.3,4
The current management for COVID-19 is maximum
supportive care, and early diagnosis may help minimize
adverse outcomes among patients.5 However, asymptomatic carriers may represent up to 42% of all infected
patients,6 conﬁrmed by the observation of high viral titers
in the absence of symptoms.7,8 In addition, reverse transcription polymerase chain reaction (RT-PCR) laboratory
testing has raised concerns regarding processing speed,
sensitivity, and availability.9 Thus, novel detection strategies are necessary to supplement traditional screening
methods and facilitate early diagnosis and mitigation of
viral transmission.
Indeed, recent data support the diagnostic consistency
and potential value of diagnostic computed tomography
(CT) scans to aid early diagnosis of COVID-19. Sensitivity
with CT has been reported to be as high as
97%9dsigniﬁcantly higher than that of RT-PCR alone,
particularly during early phases of disease.10 A direct
comparison of the 2 detection methods among 1014 Wuhan
patients resulted in positive conﬁrmations among 88% with
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Figure 1 The reference image on the right represents the computed tomography (CT) simulation study obtained 20 days before the
start of stereotactic body radiation therapy (SBRT) to a left upper lobe non-small cell lung cancer (NSCLC). The daily CT-on-rails
(CTOR) imaging from the ﬁrst fraction of treatment demonstrated new bilateral multifocal ground glass opacities concerning for
coronavirus disease 2019 (COVID-19) infection.14

CT imaging versus 59% with RT-PCR, and up to 93% of
patients were deemed positive with CT before conﬁrmation
via RT-PCR testing.9 That being said, speciﬁcity of CT was
25% alone9; thus, imaging serves as more of a complement
to rapid detection before RT-PCR conﬁrmation.
Volumetric imaging with CT-on-rails (CTOR) or cone
beam CT (CBCT) is commonly employed in patients
undergoing radiation therapy as part of daily alignment.
Previous reports have shown that imaging as part of a
radiation therapy treatment course may identify nononcologic ﬁndings such as effusion, postobstructive atelectasis, or infection. Likewise, posttreatment imaging
after radiation therapy often identiﬁes well-characterized
imaging changes such as radiation pneumonitis.11-13 Such
imaging ﬁndings may often be confounded with infection
and may be particularly problematic when assessing patients at risk for COVID-19.
This case series describes the presentation of SARSCoV-2 infections among oncologic patients undergoing
radiation therapy from a multi-institutional group of radiation oncology centers in the United States. In this
article, we highlight the clinical symptoms, daily imaging
ﬁndings, potential confounders, and clinical workﬂow to
triage these patients to the next level of care.

guidance and patient set-up before treatment delivery,
revealed new multifocal ground glass opacities (GGOs) of
the bilateral lungs, compared with her CT-simulation scan
obtained just 20 days beforehand for treatment planning
(shown in Fig 1). The treatment was performed (before
the ﬁrst of 4 planned fractions), and she was referred to
the emergency department with the CTOR images
uploaded into the patient’s electronic health record for
provider review. Although the patient was asymptomatic
without fever or acute respiratory symptoms and her examination was unremarkable, she tested positive for
SARS-CoV-2 via nasopharyngeal swab RT-PCR. Upon
notiﬁcation, the patient was instructed on home quarantine precautions, and treatment was subsequently deferred
as per departmental policy. All staff members involved in
her treatment were rapidly notiﬁed, screened, and cleared
without quarantine. Of note, a repeat test 18 days later
again returned as positive, despite the absence of symptom development. She has been tentatively rescheduled
for another CT simulation for treatment replanning 14
days after this second positive test, assuming she remains
asymptomatic during this interval.

Cases

Case 2 was a 64-year-old woman who presented in early
February with a diagnosis of cT1bN0M0 left upper lobe
non-small cell lung cancer, diagnosed after surveillance
lung CT demonstrated growth of a nodule. The patient’s
past medical history was signiﬁcant for chronic obstructive
pulmonary disease (% of forced expiratory volume at 1
second [FEV1] predicted at 63%, and % of diffusion capacity for carbon monoxide [DLCO] predicted of 42%).
She had a history of being a former smoker, with a 70-pack
year history. Based on the nodule’s growth on surveillance

Case 1
Case 1 was a 63-year-old woman, a former smoker
without signiﬁcant comorbidities, with recurrent adenocarcinoma who presented for deﬁnitive stereotactic ablative radiation therapy to 50 Gy in 4 fractions for a 7-mm
tumor of the left upper lobe.14 CTOR, obtained for image

Case 2
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Figure 2 The ﬁrst image is an axial image from the computed tomography (CT) simulation study of case 2, obtained 9 days before
start of stereotactic body radiation therapy (SBRT) to the left upper lobe lesion (not shown). The second image is the cone beam CT
(CBCT) taken before the ﬁrst fraction of treatment. On day 2, the patient began to experience increasing shortness of breath and cough.
On the third fraction of treatment, peripheral ground glass opacities were seen in the right upper lobe, out of the treatment ﬁeld, which
were new compared with the ﬁrst 2 images shown here.

lung CT and ﬂuorodeoxyglucose-avidity on positron
emission tomography and CT (30.3), a clinical diagnosis of
non-small cell lung cancer was made. After the patient was
deemed to be a high-risk operable candidate, she was
recommended for stereotactic body radiation therapy
(SBRT) as deﬁnitive management. She underwent CT
simulation in mid-March for SBRT (55 Gy/5 daily
consecutive fractions), and her ﬁrst treatment was delivered 10 calendar days later. However, at the time of her ontreatment visit the patient reported increased severity of her
baseline cough and shortness of breath, several episodes of
posttussive emesis, and increased fatigue not relieved by
rest. On review of her CBCT imaging, it was found that she
had new GGOs in the right lower lobe (Fig 2). Based on
these symptoms and ﬁndings, the institution’s COVID
hotline was immediately notiﬁed on April 1, 2020. However, because the patient did not meet the criteria at that
time for COVID-19 screening (fever, sick contacts, or
travel), she was not recommended for testing. Given the
continued clinical concern for both her symptoms and new
ﬁndings on CBCT, direct communication was made with
an infectious disease physician at the institution, who
recommended she be treated as a presumed COVID-19positive patient, and she was approved for testing. She
was given a mask and instructed to start home quarantine.
Three days later her test returned as negative for SARSCoV-2 RNA. However, given the continued high index
of suspicion for COVID-19, the patient remains in quarantine, with a plan to complete her ﬁnal 2 fractions of
SBRT once she has been asymptomatic for 3 days. The
new imaging ﬁndings are still attributed to her potential
COVID-19 diagnosis, in the absence of any conﬁrmed
alternative.

Case 3
Case 3 was a 66-year-old woman with T1bN2M0,
stage IIIA small cell lung cancer of the right upper lobe.
The patient’s medical history includes emphysema,
obstructive sleep apnea, and nonspeciﬁc pulmonary
nodules that had been followed on chest CT, ultimately
leading to the current diagnosis. The patient was a
former smoker who quit over a decade ago but had a 74pack-year smoking history. The patient was treated with
curative intent twice-daily thoracic radiation therapy
concurrent with carboplatin and etoposide. All institutional radiation dose-volume parameters were within
tolerance, the mean lung radiation dose was 9.3 Gy, and
the volume of lung receiving 20 Gy was 19.8%.
Chemoradiation was well tolerated with acute toxicities
including grade 1 cough and grade 1 esophagitis.
Approximately 9 weeks after radiation therapy, the patient called reporting a 2-day history of a new nonproductive cough with increased dyspnea and increased use
of albuterol. The patient denied fever, fatigue, or a
decreased appetite. The patient asked if her current
symptoms could be toxicities from her radiation treatment. At the time of her call, there was an intensiﬁcation
of the local COVID-19 epidemic. The patient was
counseled on radiation pneumonitis (RP) and the potential need to start treatment with a high-dose corticosteroid taper. No repeat imaging was obtained at the
time. However, out of caution she was recommended to
undergo testing for COVID-19. The COVID-19 qualitative RNA test returned positive. The patient was not
treated for RP, but rather, referred for COVID-19
management.
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Discussion
Radiation oncology clinics around the world are
currently working diligently to protect both patients and
staff from the morbidity and mortality of COVID-19.15,16
However, this pandemic has presented at a time when
many patients are either beginning or currently receiving
cancer treatment. There continues to be a ﬁne balance
between triaging patient symptoms (which for thoracic
patients may have some overlap with COVID-19 symptoms) and not introducing delays in oncologic care. In this
series of teaching cases, we presented a range of presentations of COVID-19. Although the cases here represent patients who had both positive and negative COVID19 testing, it should be noted that even patients with
negative testing were still clinically managed as presumed
positives with home quarantine and symptom
surveillance.
Incidental imaging ﬁndings suspicious for COVID-19
on diagnostic chest CTs have been increasingly reported.17 Early features described to date include bilateral
peripheral GGOs, which can be multifocal or multilobar
in appearance.18-20 With increasing clinical severity, imaging demonstrates increased extent, density, and number
of these GGOs.21,22 Resolution is accompanied by
decrease and resorption of nodular opacities bilaterally.
The use of CT image guidance for patients receiving
radiation therapy to the chest or thorax for lung, esophageal, and breast malignancies presents a unique opportunity to screen for COVID-speciﬁc lung changes. This
was recently highlighted as a case study on the Radiation
Oncology Incident Learning System (RO-ILS).23 Recommendations from RO-ILS included having radiation
therapists, physicists, dosimetrists, and physicians
become familiar with and screen for these characteristic
COVID-19 ﬁndings daily and triage patients with ﬁndings
for further evaluation. It was also recommended that
clinical practices report these events to RO-ILS to help
determine the prevalence of these ﬁndings.
Note that a prudent differential is still necessary, as
patients being treated for thoracic malignancies may have
signiﬁcant baseline pulmonary comorbidities. Additionally, patients who have a history of systemic therapy,
particularly immunotherapy, may also have pulmonary
parenchymal changes over time.24 However, as shown in
the cases presented here, the rapidity of inﬁltrate
appearance on treatment should prompt immediate
attention by the treating physician for symptom screening,
vital signs, and appropriate triage to institutional COVID
testing. Conversely, negative CBCTs should not be used
to clinically “clear” patients who are having other
COVID-associated symptoms, such as fever, new or
worsening cough, new or worsening shortness of breath,
or pleuritis. In a retrospective series of more than 120
COVID-19-positive patients across 4 medical centers in
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China, diagnostic CT images were compared by duration
of time between symptom presentation and imaging.25
For patients receiving CT imaging 0 to 2 days from
initiation of symptoms, 56% of these “early scans” were
negative, whereas only 10% of intermediate scans at 3 to
5 days from symptoms and 4% of late scans at 6 to 12
days from symptoms were negative. Therefore, prescreening of patient symptoms via nursing staff before CT
simulation study and daily screening questions before
treatment still represent a crucial part of clinical practice.
Another clinical scenario presented here illustrates the
need to have a high index of suspicion for COVID-19 for
patients who are weeks to months out from the time of
completion of thoracic radiation therapy. During this
pandemic, patients with a history of thoracic radiation
therapy who are suspected of having RP require attention.
The characteristic symptoms of RP include progressive
shortness of breath, cough, and fatigue, with or without a
low-grade fever occurring weeks to several months after
thoracic radiation. These symptoms overlap with those of
COVID-19. Given the increasing prevalence of COVID19, patients who present for RP evaluation should be
tested for COVID-19, especially if they are to be started
on empirical high-dose corticosteroids. Data indicate that
corticosteroid therapy can worsen COVID-19-associated
lung injury.26 Additionally, careful review of chest CT
imaging, if available, is recommended given that the
diffuse and multilobar radiographic features of COVID1927 contrast with the classic CT appearance of RP that is
mostly limited to the radiation ﬁeld.
Patients actively undergoing radiation therapy should
have treatment paused upon suspicion for COVID-19,
pending screening test results. For those who test positive,
robust data are lacking regarding the appropriate timeframe for radiation therapy resumption. The Centers for
Disease Control has provided guidelines on nontesting
strategy criteria for ending transmission-based precautions in the health care setting,28,29 which may be
adopted for these scenarios pending stronger evidence. A
test-based strategy is also outlined requiring 2 consecutive
negative test results (collected at least 24 hours apart),
although implementation may be limited owing to lack of
test availability and capacity. Per nontesting strategy for
symptomatic patients (case 2), Centers for Disease Control requirements entail the passage of (a) 7 days since
ﬁrst appearance of symptoms and (b) 3 days since recovery (deﬁned as resolution of fever and improvement of
respiratory symptoms). However, these guidelines are
admittedly speciﬁc to isolation. Thus, more stringent
criteria and timeframes may be warranted for patients
with active cancer. As for asymptomatic patients (case 1),
our institution requires 14 days to pass from ﬁrst positive COVID-19 result (typically without need for retesting), although this 14-day timeline was cautiously
reapplied toward the patient’s second positive test date
(ordered through her local provider).
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Although usual treatment volume has decreased at
many radiation oncology centers during the COVID-19
pandemic, there are still many patients who have recently
received treatment or are currently on treatment. Although
measures such as screening questions and temperature
measurements before department check-in certainly play a
crucial role in appropriate patient triage, we are in a
unique position to use an additional resource to monitor
our high-risk patients with on-treatment daily CT imaging. Although this manuscript described 3 scenarios for
patients with thoracic malignancies, we would recommend that both the initial simulation CT and on-board
CTs acquired as part of daily image guidance of any
patient where the imaging ﬁeld of view encompasses the
chest be reviewed for new or increasing inﬁltrates,
particularly in patients with new symptoms. The entire
image set should be reviewed, superiorly to inferiorly, to
assess for potential changes. Owing to the observation
that radiologic changes may precede physical symptoms,
and considering a false negative rate ranging from 10% to
30%,9 this routine part of our daily cancer care gives us an
additional tool to monitor our patients during this unprecedented time.

References
1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2
infection: A nationwide analysis in China. Lancet Oncol. 2020;21:
335-337.
2. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics
of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:
1775-1776.
3. Kutikov A, Weinberg DS, Edelman MJ, et al. A war on two fronts:
Cancer care in the time of COVID-19. Ann Intern Med. 2020;172:
756-758.
4. Burki TK. Cancer care in the time of COVID-19. Lancet Oncol.
2020;21:628.
5. Shankar A, Saini D, Roy S, et al. Cancer care delivery challenges
amidst coronavirus disease - 19 (COVID-19) outbreak: Speciﬁc
precautions for cancer patients and cancer care providers to prevent
spread. Asian Pac J Cancer Prev. 2020;21:569-573.
6. Nishiura H, Kobayashi T, Suzuki A, et al. Estimation of the
asymptomatic ratio of novel coronavirus infections (COVID-19). Int
J Infect Dis. 2020;94:154-155.
7. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper
respiratory specimens of infected patients. N Engl J Med. 2020;382:
1177-1179.
8. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel
coronavirus in the United States. N Engl J Med. 2020;382:929-936.
9. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR
testing in coronavirus disease 2019 (COVID-19) in China: A
report of 1014 cases. Radiology. 2020, 200642.
10. Li D, Wang D, Dong J, et al. False-negative results of real-time
reverse-transcriptase polymerase chain reaction for severe acute
respiratory syndrome coronavirus 2: Role of deep-learning-based
CT diagnosis and insights from two cases. Korean J Radiol.
2020;21:505-508.
11. Clarke E, Curtis J, Brada M. Incidence and evolution of imaging
changes on cone-beam CT during and after radical radiotherapy

Advances in Radiation Oncology: JulyeAugust 2020

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

for non-small cell lung cancer. Radiother Oncol. 2019;132:121126.
Elsayad K, Kriz J, Reinartz G, et al. Cone-beam CT-guided radiotherapy in the management of lung cancer: Diagnostic and therapeutic value. Strahlenther Onkol. 2016;192:83-91.
Kwint M, Conijn S, Schaake E, et al. Intra thoracic anatomical
changes in lung cancer patients during the course of radiotherapy.
Radiother Oncol. 2014;113:392-397.
McGinnis G, Ning M, Nitsch P, et al. Rapid detection of asymptomatic COVID-19 by CT image-guidance for stereotactic ablative
radiotherapy. J Thorac Oncol. 2020;15:1085-1087.
Samiee S, Hadjilooei F, Alamolhoda M, et al. New policy and
regulation for a radiology-oncology center at the time of
COVID-19 outbreak in Tehran-Iran. Adv Radiat Oncol. 2020;5:
550-557.
Noticewala S, Koong A, Bloom E, et al. Strategies to ﬂatten the
curve during the COVID-19 pandemic in radiation oncology:
Experience from a large tertiary cancer center. Adv Radiat Oncol.
2020;5:567-572.
Qu J, Yang R, Song L, et al. Atypical lung feature on chest CT in a
lung adenocarcinoma cancer patient infected with COVID-19. Ann
Oncol Off J Eur Soc Med Oncol. 2020. https://doi.org/10.1016/
j.annonc.2020.03.001.
Pan F, Ye T, Sun P, et al. Time course of lung changes on chest
CT during recovery from 2019 novel coronavirus (COVID-19)
pneumonia. Radiology. 2020, 200370.
Pan Y, Guan H, Zhou S, et al. Initial CT ﬁndings and temporal
changes in patients with the novel coronavirus pneumonia (2019nCoV): A study of 63 patients in Wuhan, China. Eur Radiol. 2020;
30:3306-3309.
Shi H, Han X, Zheng C. Evolution of CT manifestations in a patient
recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in
Wuhan, China. Radiology. 2020;295:20.
Chung M, Bernheim A, Mei X, et al. CT imaging features of
2019 novel coronavirus (2019-nCoV). Radiology. 2020;295:
202-207.
Yoon SH, Lee KH, Kim JY, et al. Chest radiographic and CT
ﬁndings of the 2019 novel coronavirus disease (COVID-19):
Analysis of nine patients treated in Korea. Korean J Radiol. 2020;
21:494-500.
American Society for Radiation Oncology website (ASTRO).
Available at https://www.astro.org/Patient-Care-and-Research/
Patient-Safety/RO-ILS/Case-Study-05. Accessed April 9, 2020.
Kalisz K, Ramaiya NH, Laukamp KR, et al. Immune checkpoint
inhibitor therapy related pneumonitis: Patterns and management.
Radiographics. 2019;39:1923-1937.
Bernheim A, Mei XY, Huang MQ, et al. Chest CT ﬁndings in
coronavirus disease-19 (COVID-19): Relationship to duration of
infection. Radiology. doi/pdf/10.1148/radiol.2020200463.
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet.
2020;395:473-475.
Choi YW, Munden RF, Erasmus JJ, et al. Effects of radiation
therapy on the lung: Radiologic appearances and differential diagnosis. Radiographics. 2004;24:985-997. discussion, 98.
Centers for Disease Control and Prevention (CDC). Discontinuation
of Isolation for Persons with COVID-19 Not in Healthcare Settings
(Interim Guidance). Available at https://www.cdc.gov/coronavirus/2
019-ncov/hcp/disposition-in-home-patients.html. Accessed April 23,
2020.
Centers for Disease Control and Prevention (CDC). Discontinuation of
Transmission-Based Precautions and Disposition of Patients with
COVID-19 in Health care Settings (Interim Guidance). Available at
https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalizedpatients.html. Accessed April 23, 2020.

